CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2022 | $36,000 | -5.3% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $38,000 | -70.3% | 600 | -64.7% | 0.00% | -66.7% |
| Q4 2021 | $128,000 | -52.2% | 1,700 | -29.2% | 0.00% | -50.0% |
| Q3 2021 | $268,000 | -28.0% | 2,400 | +4.3% | 0.01% | -25.0% |
| Q2 2021 | $372,000 | +291.6% | 2,300 | +196.8% | 0.01% | +300.0% |
| Q1 2021 | $95,000 | +55.7% | 775 | +93.8% | 0.00% | 0.0% |
| Q4 2020 | $61,000 | +74.3% | 400 | -50.0% | 0.00% | +100.0% |
| Q3 2018 | $35,000 | -25.5% | 800 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $47,000 | – | 800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |